EPO rDNA Roche - Biotech, Pharma and Life Science Channel
PubMed Articles
Longidorus aetnaeus Roca, Lamberti, Agostinelli & Vinciguerra, 1986 is reported for the first time from Iran and Ajaria (Georgia). Morphological and morphometric data are provided for two Iranian and...
A population of Xiphinema macroacanthum Lamberti, Roca & Agostinelli, 1989 originating from olive orchards in Brindisi, Italy and containing both adults and all juvenile stages, is described and illus...
BACKGROUND AND PURPOSE: This study investigated the prognostic role of tumor cell expression of erythropoietin (EPO) and its receptor (EPO-R) in patients with locally advanced squamous cell carcinoma...
Hypoxia inducible factor (HIF) and 5'-AMP-activated protein kinase are often activated under similar physiological conditions. Constitutive androstane receptor (CAR) translocates into the nucleus in a...
Microcystins (MCs) cause normocytic anemia in patients in a hemodialysis unit in Caruaru, Brazil in 1996, but the underlying mechanisms are still unclear. In the present study, Balb/c mice were intrap...
Microsporum fulvum, an Ignored Pathogenic Dermatophyte: A New Clinical Isolation from Iran.
Misidentifying with Microsporum gypseum has for a long time been accounted for less prevalence of the geophilic species, Microsporum fulvum in human dermatophytosis. We describe a new case of infectio...
Journey of the ALK-inhibitor CH5424802 to phase II clinical trial.
The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase represents a potential therapeutic target. Specially, a variety of alterations in the ALK gene including mutations, overexpression, amplif...
Changes in DNA methylation patterns and repetitive sequences in blood lymphocytes of aged horses.
It is known that aged organisms have modified epigenomes. Epigenetic modifications, such as changes in global and locus-specific DNA methylation, and histone modifications are suspected to play an imp...
Erythropoietin (EPO) was hypothesized to mitigate reperfusion injury, in part via mobilization of endothelial progenitor cells (EPCs). The REVEAL trial found no reduction in infarct size with a single...
An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pKa and thereby dramatically change the pharmacological profile of this class of BACE1 inhibitors. The CF3 sub...
News Articles
Proposal to list Roche's Neulastim and Actemra in New Zealand
New Zealand's Pharmaceutical Management Agency PHARMAC has announce the approval of a proposal to list pegfilgrastim (Neulastim) for prevention of neutropenia in patients undergoing cancer chemotherap...
FDA allows marketing of first A1c test labeled for diagnosing diabetes, from Roche
The US Food and Drug Administration yesterday (May 23) announced that it is allowing marketing of the Cobas Integra 800 Tina-quant HbA1cDx assay (Tina-quant HbA1cDx assay) for the diagnosis of diabete...
CH-Eröffnung: Technische Erholung nach Kurseinbruch – Roche steigen
Zürich - Der Schweizer Aktienmarkt ist am Freitag mit Kursgewinnen in den Handel gestartet und kann sich etwas vom Rücksetzer des Vortags erholen. Unterstützung bieten den europäischen Börsen die...
Heptares Augments Business Development Capabilities in Japan and Other Asian Territories
WELWYN GARDEN CITY, England and BOSTON, May 24, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery and development company, is pleased to announce that it has engaged Mr Akir...
Macrocyclics, Roche in Nuclear Medicine Pact
Aims to speed up the clinical development process
In this episode of PharmaTelevision News Review, filmed at Bio Conference 2013, in Chicago, USA, Fintan Walton talks to Stefan Frings.
Peregrine Pharmaceuticals, The Little Biotech With The Golden Goose Of Immunotherapy
By Chris Lacoursiere:The annual conference of The American Society of Clinical Oncology (ASCO) is currently less than a few days away, and what is the buzz for this year's conference? Immunotherapy is...
Macrocyclics to Collaborate with Roche on Molecular Innovation for Nuclear Medicine
DALLAS, May 23, 2013 /PRNewswire/ -- After the successful completion of their first 2012 collaboration, Macrocyclics (an AREVA Med company) announced today a new collaborative research...
The new report* explains how the more advanced drugs are far outstripping their biologic predecessors in terms of sales and pricing, helping companies maintain revenue at a time when patent expiry i...
"Commit to Confidence" Hits Amazon and Barnes & Noble
Wilmington, DE (PRWEB) May 23, 2013 Just released this month on Amazon and B&N is a new book by executive coach and author Barbara Roche: âCommit to Confidence: 30 Strategies to Help Wome...
Events
12th Annual Biological Production Forum 2013
Improving your biological production performance to overcome challenges in the biomanufacturing industry
Companies
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company,...
Founded more than 35 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening me...
Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of majo...
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the worldâs largest...
Aileron Therapeutics has defined a new class of drugs called Stapled Peptides. The companyâs proprietary Stapled Peptides platform is a breakthrough approach to creating drug...
MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing for personalized medicine. The companyâs tes...
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the worldâs largest...
Nil
Berlin-based NOXXON Pharma AG is a clinical stage biotechnology company focusing on the development of Spiegelmers® for the treatment of inflammatory diseases and hematological...
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other s...
Clinical Trials
Effects of Anemia Correction on Vascular and Monocyte Function in Renal Transplant Recipients
Correction of anaemia in renal transplant recipients by parenteral application of recombinant erythropoietin and if necessary iron will improve large artery function (endothelial function...
PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation
Randomized, double blind, placebo controlled, prospective trial investigating the effect of erythropoietin in renal transplantation. The investigators postulate that erythropoietin reduc...
Erythropoietin in Acute Myocardial Infarction
Erythropoietin (EPO) is a naturally occuring hormone which regulates the body's response to lack of oxygen and controls the number of red cells in the blood. Recent studies in animals have...
Erythropoietin Therapy for Subarachnoid Hemorrhage
ABSTRACT: Delayed ischemic deficits (DID) and strokes caused by low cerebral blood flow (CBF) are major sources of poor outcome following aneurysmal subarachnoid hemorrhage (SAH). DID are...
Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS
Objectives: Primary: To evaluate the response rate of total cytokine-immunotherapy for low-risk MDS. Secondary: To evaluate response duration, survival and side effects of the treatment.
Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial
Full Title: A Randomized Controlled Trial of Procrit for the Prevention of Acute Renal Failure in Patients Receiving Intravenous Contrast Primary Objective: To evaluate the efficacy of a...
This study will compare the safety, tolerability and efficacy of aleglitazar and Actos® in patients with type 2 diabetes and symptomatic NYHA class II heart failure. Eligible patients wil...
Study of the Relationship Between rHuEPO Dose, Serum ADPN, and Mortality in Patients Beginning HD
Responsiveness of recombinant human erythropoietin (rHuEPO) is known to be related with body fatness in hemodialysis (HD) patients. Adiponectin (ADPN) is inversely associated with body fat...
Dynepo Infrequent Dosing Study
The purpose of this study is to demonstrate non-inferiority of efficacy between twice weekly and once weekly dose schedule of Dynepo in previously erythropoietin (EPO)-naive patients, as m...
Hepcidin in Anemic Chronic Heart Failure (CHF) Patients
Background: Anemia in chronic heart failure (CHF) is directly linked to increased mortality and reduced exercise capacity. The pathomechanism for the development of anemia in CHF is not...
Videos
Medical and Biotech [MESH] Definitions
Receptors, Eph Family
A large family of receptor protein-tyrosine kinases that are structurally-related. The name of this family of proteins derives from original protein Eph (now called the EPHA1 RECEPTOR), which was named after the cell line it was first discovered in: Erythropoietin-Producing human Hepatocellular carcinoma cell line. Members of this family have been implicated in regulation of cell-cell interactions involved in nervous system patterning and development.
Receptor, Epha1
The founding member of the EPH FAMILY RECEPTORS. It was first cloned from an erythropoietin-producing human hepatocellular carcinoma cell line and is highly conserved among many mammalian species. Overproduction of the EphA1 receptor is associated with tumors and tumor cells of epithelial origin. It is also expressed at high levels in LIVER; LUNG; and KIDNEY; which is in contrast to many other members of the Eph receptor that are found primarily in tissues of the nervous system.
Actinobacteria
Class of BACTERIA with diverse morphological properties. Strains of Actinobacteria show greater than 80% 16S rDNA/rRNA sequence similarity among each other and also the presence of certain signature nucleotides. (Stackebrandt E. et al, Int. J. Syst. Bacteriol. (1997) 47:479-491)
Janus Kinase 2
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
Erythroid Precursor Cells
The cells in the erythroid series derived from MYELOID PROGENITOR CELLS or from the bi-potential MEGAKARYOCYTE-ERYTHROID PROGENITOR CELLS which eventually give rise to mature RED BLOOD CELLS. The erythroid progenitor cells develop in two phases: erythroid burst-forming units (BFU-E) followed by erythroid colony-forming units (CFU-E); BFU-E differentiate into CFU-E on stimulation by ERYTHROPOIETIN, and then further differentiate into ERYTHROBLASTS when stimulated by other factors.
